Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Oculis Holding AGNASDAQ: OCS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 58.91M shares rose 22.1% year over year, behind the +27.5% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 5.2% from the prior quarter. Over 3 fiscal years it compounded at +16.9% a year.

Context

  • Weighted avg shares increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +22.1% toward the trailing-twelve-month pace of +27.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
58.91M+5.2% QoQ
Last fiscal yearDec 2025
52.36M+29.6% YoY
LTMMar 2026
54.96M+27.5% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.1%——
1 year+29.6%——
3-year CAGR+16.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
52.36M CHF
Year-over-year change
+29.6%
4-year CAGR
+12.5%

Weighted Avg Shares vs competitors

How OCS compares with its peers on the latest reported figures

  • OCS's LTM Mar 2026 weighted avg shares of 54.96M shares is the 3rd highest of the 6 companies compared; the peer median is 53.45M shares.
  • Its year-over-year change of +27.5% is the 4th highest of 6, against a peer median of +27.7%.
  • Over three fiscal years its annual growth of +16.9% compares with a peer median of +34.5%.
OCS Competitors Peer median
Weighted Avg Shares for OCS and competitors
Company Period LTM YoY 3-year CAGR
OCULOcular Therapeutix, Inc.LTM Mar 2026200.88M +19.9%+34.5%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202677.28M +27.7%+25.2%
OCSOculis Holding AGLTM Mar 202654.96M +27.5%+16.9%
OTLKOutlook Therapeutics, Inc.LTM Mar 202653.45M +120.6%+48.6%
OKYOOKYO Pharma LimitedFY202539.49M +34.6%+37.9%
HROWHarrow Health, Inc.LTM Mar 202636.98M +3.5%+10.2%
Peer median (excluding OCS) 53.45M+27.7%+34.5%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue000686K0
Cost of Revenue00052.08M0
Gross Profit000(51.4M)0
Gross Margin———-7492.3%—
Research & Development9.57M22.22M29.25M52.08M54.52M
Selling, General & Admin4.1M6.74M14.72M21.81M24.63M
Operating Expenses13.23M32.38M80.71M21.81M79.15M
Depreciation & Amortization235K299K287K406K521.45K
EBITDA(13.17M)(31.9M)(87.09M)(85.53M)(93.37M)
EBITDA Margin———-12468.1%—
Operating Income(13.23M)(32.38M)(80.71M)(73.2M)(79.15M)
Operating Margin———-10671.1%—
Interest Income21K126K1.59M2.17M1.69M
Interest Expense5.12M6.44M1.46M639K795.55K
Other Income / Expenses(5.29M)(6.27M)(7.98M)(12.73M)(15.54M)
Income Before Tax(18.52M)(38.64M)(88.7M)(85.94M)(94.69M)
Pre-Tax Margin———-12527.3%—
Income Tax Expense27K55K107K(160K)177.64K
Net Income(18.55M)(38.7M)(88.8M)(85.78M)(94.51M)
Net Margin———-12503.9%—
EPS (Basic)(0.57)(1.18)(2.97)(2.12)(1.81)
EPS (Diluted)(0.57)(1.18)(2.97)(2.12)(1.81)
Weighted Avg Shares32.73M32.73M29.9M40.41M52.36M
Weighted Avg Shares (Diluted)32.73M32.73M29.9M40.41M52.36M

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.